77
Participants
Start Date
October 6, 2021
Primary Completion Date
January 3, 2024
Study Completion Date
November 25, 2024
SEA-CD40
Given into the vein (IV; intravenously); schedule is cohort-specific
pembrolizumab (KEYTRUDA®)
Given by IV; schedule is cohort-specific.
pemetrexed
Given by IV on Day 1 of each 21-day cycle.
carboplatin
Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
Thomas Jefferson University, Philadelphia
Duke University Medical Center, Durham
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid
University Cancer & Blood Center, LLC, Athens
Florida Cancer Specialists - North Region, St. Petersburg
Florida Cancer Specialists - South Region, Fort Myers
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville
Cleveland Clinic - Taussig Cancer Institute, Cleveland
Gabrail Cancer Center Research, LLC, Canton
Hospital Clinico Universitario de Valencia, Valencia
Community Health Network, Indianapolis
Carbone Cancer Center / University of Wisconsin, Madison
Regions Cancer Care Center, Saint Paul
Allina Health Cancer Institute, Minneapolis
University of Minnesota, Minneapolis
Rush University Medical Center, Chicago
Universitatsklinikum Heidelberg, Heidelberg
American Oncology Networks LLC, Baton Rouge
Highlands Oncology Group, Springdale
University of Texas Southwestern/Simmons Cancer Center, Dallas
The Angeles Clinic and Research Institute, Los Angeles
Hopital Foch, Suresnes
California Pacific Medical Center Research Institute/Sutter Medical Centre, San Francisco
University of California at San Francisco, San Francisco
Kaiser Permanente Oregon, Portland
Morristown Medical Center/ Carol G. Simon Cancer Center, Morristown
MD Anderson Cancer Center / University of Texas, Houston
CHU de Quebec-Universite Laval, Québec
Karolinska University Hospital, Stockholm
Merck Sharp & Dohme LLC
INDUSTRY
Seagen Inc.
INDUSTRY